BAFNAPHPharmaceuticals
Bafna Pharmaceuticals Ltd — Profit & Loss Statement
₹109.34
-4.38%
Bafna Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 10757.01 | 0.00 | — |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.02 | 0.00 | — |
| Normalized EBITDA | 13.92 Cr | 14.63 Cr | 18.70 Cr | 13.36 Cr | — |
| Total Unusual Items | -2.15 Cr | 0.00 | 0.04 Cr | -2.12 Cr | — |
| Total Unusual Items Excluding Goodwill | -2.15 Cr | 0.00 | 0.04 Cr | -2.12 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Reconciled Depreciation | 4.89 Cr | 5.00 Cr | 5.33 Cr | 5.49 Cr | — |
| Reconciled Cost Of Revenue | 103.06 Cr | 106.91 Cr | 76.59 Cr | 51.28 Cr | — |
| EBITDA | 11.77 Cr | 14.63 Cr | 18.75 Cr | 11.23 Cr | — |
| EBIT | 6.88 Cr | 9.64 Cr | 13.41 Cr | 5.74 Cr | — |
| Net Interest Income | -2.73 Cr | -2.29 Cr | -1.99 Cr | -0.76 Cr | — |
| Interest Expense | 2.73 Cr | 2.29 Cr | 1.80 Cr | 0.52 Cr | — |
| Normalized Income | 6.30 Cr | 7.35 Cr | 11.29 Cr | 7.34 Cr | — |
| Net Income From Continuing And Discontinued Operation | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Total Expenses | 139.57 Cr | 146.35 Cr | 103.28 Cr | 78.53 Cr | — |
| Diluted Average Shares | 2.36 Cr | 2.36 Cr | 2.37 Cr | 2.37 Cr | — |
| Basic Average Shares | 2.36 Cr | 2.36 Cr | 2.37 Cr | 2.37 Cr | — |
| Diluted EPS | 1.76 | 3.11 | 4.79 | 2.21 | — |
| Basic EPS | 1.76 | 3.11 | 4.79 | 2.21 | — |
| Diluted NI Availto Com Stockholders | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Net Income Common Stockholders | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Net Income Including Noncontrolling Interests | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Net Income Continuous Operations | 4.15 Cr | 7.35 Cr | 11.34 Cr | 5.22 Cr | — |
| Tax Provision | 0.00 | 0.00 | 0.28 Cr | 0.00 | — |
| Pretax Income | 4.15 Cr | 7.35 Cr | 11.62 Cr | 5.22 Cr | — |
| Other Non Operating Income Expenses | 2.74 Cr | 3.52 Cr | 0.02 Cr | 1.13 Cr | — |
| Special Income Charges | -2.15 Cr | 0.00 | 0.04 Cr | -2.12 Cr | — |
| Net Non Operating Interest Income Expense | -2.73 Cr | -2.29 Cr | -1.99 Cr | -0.76 Cr | — |
| Interest Expense Non Operating | 2.73 Cr | 2.29 Cr | 1.80 Cr | 0.52 Cr | — |
| Operating Income | 6.29 Cr | 6.12 Cr | 12.07 Cr | 6.61 Cr | — |
| Operating Expense | 36.51 Cr | 39.44 Cr | 26.69 Cr | 27.25 Cr | — |
| Other Operating Expenses | 10.59 Cr | 15.42 Cr | 3.86 Cr | 3.02 Cr | — |
| Depreciation And Amortization In Income Statement | 4.89 Cr | 5.00 Cr | 5.33 Cr | 5.49 Cr | — |
| Depreciation Income Statement | 4.89 Cr | 5.00 Cr | 5.33 Cr | 5.49 Cr | — |
| Gross Profit | 42.80 Cr | 45.56 Cr | 38.76 Cr | 33.86 Cr | — |
| Cost Of Revenue | 103.06 Cr | 106.91 Cr | 76.59 Cr | 51.28 Cr | — |
| Total Revenue | 145.86 Cr | 152.47 Cr | 115.35 Cr | 85.14 Cr | — |
| Operating Revenue | 145.86 Cr | 152.47 Cr | 115.35 Cr | 85.14 Cr | — |
| Interest Income | — | 0.13 Cr | 0.04 Cr | 0.03 Cr | 0.04 Cr |
| Rent Expense Supplemental | — | 0.21 Cr | 0.21 Cr | 0.19 Cr | 0.21 Cr |
| Other Special Charges | — | -0.07 Cr | -0.35 Cr | 2.15 Cr | — |
| Write Off | — | 0.07 Cr | 0.30 Cr | -0.02 Cr | 0.00 |
| Total Other Finance Cost | — | 0.35 Cr | 0.24 Cr | 0.27 Cr | 0.65 Cr |
| Interest Income Non Operating | — | 0.13 Cr | 0.04 Cr | 0.03 Cr | 0.04 Cr |
| Research And Development | — | 0.27 Cr | 0.72 Cr | 1.47 Cr | — |
| Selling General And Administration | — | 8.53 Cr | 2.04 Cr | 2.58 Cr | 0.78 Cr |
| Selling And Marketing Expense | — | 0.60 Cr | 0.56 Cr | 0.59 Cr | 0.06 Cr |
| General And Administrative Expense | — | 7.93 Cr | 1.48 Cr | 1.99 Cr | 0.72 Cr |
| Rent And Landing Fees | — | 0.21 Cr | 0.21 Cr | 0.19 Cr | 0.21 Cr |
| Net Income Extraordinary | — | — | — | -2.16 Cr | 0.00 |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bafna Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.